Eton Pharmaceuticals, Inc. ETON 深 沪
已收盘 02-06 16:00:00 美东时间
14.76
+0.410
+2.86%
华盛通- 最 高15.01
- 今 开14.60
- 成交量 22.88万股
- 最 低 14.522
- 昨 收 14.35
- 总市值 3.96亿
- 52周最高 23.00
- 市盈率 静 --
- 换手率 0.85%
- 52周最低 11.0867
- 委 比 41.41%
- 总股本 2681.75万
- 历史最高 23.00
- 量 比 1.00
- 振 幅 3.40%
- 历史最低 1.95
- 每 手 1
- 风险率 2.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Eton Pharma Announces Licensing Of U.S. Marketing Rights To Ultra-Rare Disease Product Candidate; Product Is Currently Under Review With FDA; Potential Approval And Launch Mid-2026
Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the
02-02 19:51
Eton Pharmaceuticals Joins Piper Sandler Healthcare Conference
The latest announcement is out from Eton Pharmaceuticals ( ($ETON) ). On Decemb...
2025-12-04 20:58
Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th
Eton Pharmaceuticals announced that its executive leadership team will host a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in NYC on December 4, 2025, at 9:30 AM ET. The Company, focused on rare disease treatments, currently has eight commercial products and five late-stage product candidates. For更多信息, please visit www.etonpharma.com.
2025-11-24 21:30
电话会总结 ｜ Eton Pharma(ETON)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Eton Pharmaceuticals业绩会实录，以下是Q3 2025财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** Q3 2025产品收入达2,250万美元，同比增长129%，环比增长19%，实现连续第19个季度的环比增长。增长主要由Alkindi Sprinkle、kerglumic acid以及新收购的Incralex和Galzin产品驱动。 **盈利能力：** 调整后毛利润为1,020万美元，调整后毛利率为45%，较去年同期的64%有所下降。调整后EBITDA为290万美元，较去年同期的200万美元有所改善。 **净利润：
2025-11-10 12:05
Eton Pharmaceuticals shares are trading lower after the company reported mixed Q3 financial results.
Eton Pharmaceuticals shares are trading lower after the company reported mixed ...
2025-11-07 06:21
Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference
DETON Pharmaceuticals announced that its executive team will hold 1x1 meetings at the 2025 Wells Fargo Healthcare Conference in Boston. The company focuses on developing treatments for rare diseases and currently has eight commercial products. Additional details can be found on their website.投资者如需安排会议，请联系Wells Fargo的机构销售代表。
2025-08-20 10:50
Eton Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 sales results.
Eton Pharmaceuticals shares are trading higher after the company reported bette...
2025-08-08 05:06
Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Eton Pharmaceuticals, Inc. announced it will report second quarter 2025 financial results on August 7, 2025, with a conference call and live webcast at 4:30 p.m. ET. Participants can join by dialing (800) 715-9871 or (646) 307-1963 with conference ID 5899895 or via webcast. Investors can submit questions via email to investorrelations@etonpharma.com. The webcast will be available on Eton’s website, with an archived version posted two hours post-e...
2025-07-28 11:00
Eton gains as hormonal disorder therapy undergoes FDA review
Shares of Eton Pharmaceuticals (NASDAQ:ETON) added ~8% in the premarket on Tuesday after the FDA agreed to review its marketing application for ET-600, a potential treatment for a rare hormonal disord...
2025-07-08 19:33
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
Eton Pharmaceuticals announced the FDA acceptance of its New Drug Application (NDA) for ET-600, a proprietary desmopressin oral solution for treating central diabetes insipidus (AVP-D). The FDA has set a target action date of February 25, 2026, and the product is patented through 2044. ET-600 addresses a significant unmet need by offering an accurate, titratable liquid solution for pediatric patients. Eton has initiated commercial preparations fo...
2025-07-08 10:50
